Author Archives: Thomas Payne

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting

By

TScan Therapeutics Announces Closing of Public Offering

By

TScan Therapeutics to Participate in the Jefferies Healthcare Conference

By

TScan Therapeutics Announces Pricing of $140 Million Public Offering

By

TScan Therapeutics Announces Launch of Proposed Public Offering

By

TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors

By

TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting

By

TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

By

Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease

By

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting

By